Affordable Access

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.

Authors
  • Garcia-Carbonero, R
  • Supko, J G
  • Maki, R G
  • Manola, J
  • Ryan, D P
  • Harmon, D
  • Puchalski, T A
  • Goss, G
  • Seiden, M V
  • Waxman, A
  • Quigley, M T
  • Lopez, T
  • Sancho, M A
  • Jimeno, J
  • Guzman, C
  • Demetri, G D
Type
Published Article
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publication Date
Aug 20, 2005
Volume
23
Issue
24
Pages
5484–5492
Identifiers
PMID: 16110008
Source
Medline
License
Unknown

Abstract

ET-743 demonstrates clinical activity as first-line therapy against STS with acceptable toxicity. Additional studies to establish empirical dosing guidelines may be necessary to improve the safety of the drug in patients with varying degrees of hepatic dysfunction and definitively establish the role of ET-743 for patients with these malignancies.

Report this publication

Statistics

Seen <100 times